Analysts Set Expectations for Haemonetics Co.’s Q1 2025 Earnings (NYSE:HAE)

Haemonetics Co. (NYSE:HAE) – Equities researchers at Zacks Research upped their Q1 2025 earnings per share estimates for Haemonetics in a note issued to investors on Tuesday, April 30th. Zacks Research analyst R. Department now expects that the medical instruments supplier will post earnings per share of $0.96 for the quarter, up from their prior forecast of $0.95. The consensus estimate for Haemonetics’ current full-year earnings is $3.95 per share. Zacks Research also issued estimates for Haemonetics’ Q2 2025 earnings at $1.06 EPS, Q3 2025 earnings at $1.09 EPS and FY2025 earnings at $4.17 EPS.

HAE has been the topic of several other research reports. Barrington Research reiterated an “outperform” rating and issued a $105.00 price objective on shares of Haemonetics in a report on Friday, April 12th. TheStreet cut Haemonetics from a “b-” rating to a “c+” rating in a report on Thursday, February 29th. Finally, StockNews.com cut Haemonetics from a “buy” rating to a “hold” rating in a report on Friday, March 22nd.

Haemonetics Trading Up 0.3 %

NYSE HAE opened at $92.26 on Thursday. The stock’s 50-day simple moving average is $81.58 and its two-hundred day simple moving average is $82.67. Haemonetics has a twelve month low of $70.74 and a twelve month high of $95.26. The company has a quick ratio of 1.76, a current ratio of 2.92 and a debt-to-equity ratio of 0.91. The company has a market capitalization of $4.69 billion, a price-to-earnings ratio of 37.50, a PEG ratio of 2.17 and a beta of 0.34.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, February 8th. The medical instruments supplier reported $1.04 earnings per share for the quarter, beating analysts’ consensus estimates of $0.94 by $0.10. Haemonetics had a return on equity of 22.37% and a net margin of 9.97%. The business had revenue of $336.20 million for the quarter, compared to the consensus estimate of $320.84 million. During the same quarter last year, the business posted $0.85 earnings per share. The company’s revenue for the quarter was up 10.1% on a year-over-year basis.

Hedge Funds Weigh In On Haemonetics

A number of institutional investors have recently bought and sold shares of the stock. Raymond James & Associates increased its stake in Haemonetics by 11.6% in the 3rd quarter. Raymond James & Associates now owns 32,801 shares of the medical instruments supplier’s stock worth $2,938,000 after buying an additional 3,421 shares in the last quarter. Bailard Inc. increased its stake in Haemonetics by 11.8% in the 3rd quarter. Bailard Inc. now owns 2,835 shares of the medical instruments supplier’s stock worth $254,000 after buying an additional 300 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Haemonetics by 58.4% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,446 shares of the medical instruments supplier’s stock worth $1,204,000 after buying an additional 4,959 shares in the last quarter. TD Asset Management Inc purchased a new stake in Haemonetics in the 3rd quarter worth $2,114,000. Finally, Carmel Capital Partners LLC purchased a new stake in Haemonetics in the 3rd quarter worth $30,000. 99.67% of the stock is owned by institutional investors.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.